Thermo Fisher Expands its Direct-to-Patient Service Offerings

 Thermo Fisher Expands its Direct-to-Patient Service Offerings

Thermo Fisher Expands its Direct-to-Patient Service Offerings

Shots:

  • The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates
  • The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020 to ensure that clinical trial patients have uninterrupted access to life-saving drug shipments without visiting a clinic
  • The Direct-to-Patient services include Pharmacy-to-Patient, Depot-to-Patient, and Clinical Site-to-Patient services, enabling clinical trial medication delivered directly to patients’ homes. Clinical Site-to-Patient services are available in 47 countries, supporting 1,500+ shipments to patients globally

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Tele Trader

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post